LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

Search

SpringWorks Therapeutics Inc

Cerrado

SectorSanidad

46.2

Resumen

Variación precio

24h

Actual

Mínimo

46.09

Máximo

46.21

Métricas clave

By Trading Economics

Ingresos

-24M

-77M

Ventas

12M

62M

BPA

-1.04

Margen de beneficios

-125.586

Empleados

368

EBITDA

-23M

-80M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+27.16% upside

Dividendos

By Dow Jones

Próximas Ganancias

15 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-677M

3.5B

Apertura anterior

46.2

Cierre anterior

46.2

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

195 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

SpringWorks Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

28 abr 2025, 11:25 UTC

Adquisiciones, fusiones, absorciones

Germany's Merck to Buy SpringWorks for $3.9 Billion -- Update

28 abr 2025, 06:41 UTC

Adquisiciones, fusiones, absorciones

Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal

11 feb 2025, 07:03 UTC

Adquisiciones, fusiones, absorciones

Germany's Merck in Talks to Buy SpringWorks Therapeutics

10 feb 2025, 16:38 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

SpringWorks Therapeutics Shares Rise on Report it May be Acquired

28 abr 2025, 15:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Merck KGaA's $3.9B SpringWorks Therapeutics Buy Underwhelms -- Market Talk

28 abr 2025, 09:20 UTC

Acciones populares

Stocks to Watch Monday: DoorDash, Merck, Spirit AeroSystems, Airbus -- WSJ

28 abr 2025, 06:06 UTC

Adquisiciones, fusiones, absorciones

Germany's Merck: Acquisition Will Strengthen Merck Healthcare Presence in U.S.

28 abr 2025, 06:05 UTC

Adquisiciones, fusiones, absorciones

Germany's Merck: Planned Acquisition Will Immediately Add Revenue, Accelerate Growth

28 abr 2025, 06:05 UTC

Adquisiciones, fusiones, absorciones

Germany's Merck: Deal Is for Purchase Price of $47 a Share in Cash

28 abr 2025, 06:04 UTC

Adquisiciones, fusiones, absorciones

Germany's Merck to Buy SpringWorks for About $3.9B

28 abr 2025, 06:02 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Germany's Merck to Buy SpringWorks Therapeutics

24 abr 2025, 22:51 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 abr 2025, 20:54 UTC

Adquisiciones, fusiones, absorciones

Merck KGaA: No Final Decision Has Been Taken; No Legally Binding Agreement Has Been Entered Into

24 abr 2025, 20:50 UTC

Adquisiciones, fusiones, absorciones

Merck KGaA Confirms Late-Stage Discussions With SpringWorks Therapeutics on Potential Acquisition for About 47c a Share

24 abr 2025, 19:05 UTC

Adquisiciones, fusiones, absorciones

Merck KGaA Expected to Pay Close to $47 a Share for SpringWorks, Sources Say -- WSJ

24 abr 2025, 19:05 UTC

Adquisiciones, fusiones, absorciones

Merck KGaA, SpringWorks Deal Expected to Be Finalized as Soon as Monday, Sources Say -- WSJ

24 abr 2025, 19:05 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- WSJ

24 abr 2025, 19:05 UTC

Adquisiciones, fusiones, absorciones

Merck KGaA Nears Roughly $3.5 Billion Takeover of SpringWorks Therapeutics, Sources Say -- WSJ

11 feb 2025, 10:54 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk

11 feb 2025, 10:52 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

Comparación entre iguales

Cambio de precio

SpringWorks Therapeutics Inc previsión

Precio Objetivo

By TipRanks

27.16% repunte

Estimación a 12 Meses

Media 58.75 USD  27.16%

Máximo 84 USD

Mínimo 47 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para SpringWorks Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

8 ratings

3

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

46.18 / 46.305Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Very Strong Bullish Evidence

Sentimiento

By Acuity

195 / 382 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.